Gemcitabine for relapsed or resistant lymphoma
Annals of Oncology, 2000 Gemcitabine therapy has not been widely assessed in the treatment of hematological malignancies. We have examined the efficacy and safety of gemcitabine in patients with relapsed or resistant lymphoma.Gemcitabine (1 g/m2) was given weekly for 7 consecutive weeks, followed by a week off treatment.
D G, Savage +10 more
openaire +2 more sources
Gemcitabine in Bone Sarcoma Resistant to Doxorubicin‐BasedChemotherapy [PDF]
Sarcoma, 2000 Subjects and Methods: Seven patients with progressive localized or metastatic chemo‐resistant osteosarcoma were treated by gemcitabine.The protocol included gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest.
Merimsky, Ofer +5 more
openaire +2 more sources
Journal of Experimental & Clinical Cancer Research, 2023 Background Gemcitabine resistance has brought great challenges to the treatment of pancreatic cancer. The N6-methyladenosine (m6A) mutation has been shown to have a significant regulatory role in chemosensitivity; however, it is not apparent whether ...
Kai Lin +8 more
doaj +1 more source
Methionine Adenosyltransferase 1a (MAT1A) Enhances Cell Survival During Chemotherapy Treatment and is Associated with Drug Resistance in Bladder Cancer PDX Mice. [PDF]
, 2019 Bladder cancer is among the top ten most common cancers, with about ~380,000 new cases and ~150,000 deaths per year worldwide. Tumor relapse following chemotherapy treatment has long been a significant challenge towards completely curing cancer.
de Vere White, Ralph +8 more
core +2 more sources
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. [PDF]
PLoS ONE, 2012 Although gemcitabine is highly active in several cancer types, intrinsic and acquired drug resistance remains a major challenge. Overexpression of Bcl-2 has been associated with gemcitabine resistance.
Foong Ying Wong +6 more
doaj +1 more source
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. [PDF]
, 2018 Expression of the chromatin-associated protein HMGA2 correlates with progression, metastasis and therapy resistance in pancreatic ductal adenocarcinoma (PDAC). Hmga2 has also been identified as a marker of a transient subpopulation of PDAC cells that has
Chiou, Shin-Heng +7 more
core +1 more source
Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer. [PDF]
, 2018 BACKGROUND:Although canonical Wnt signaling is known to promote tumorigenesis in pancreatic ductal adenocarcinoma (PDAC), a cancer driven principally by mutant K-Ras, the detailed molecular mechanisms by which the Wnt effector β-catenin regulates such ...
Chen, Yibu +12 more
core +2 more sources
Chemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer
Frontiers in Oncology, 2022 Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Gemcitabine is the most commonly used chemotherapy for the treatment of PDAC, but the development of drug resistance still remains challenging.
Xinyuan Li +6 more
doaj +1 more source
14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression [PDF]
, 2016 Gemcitabine is an important anticancer therapeutics approved for treatment of several human cancers including locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
Dong, Zizheng, Qin, Li, Zhang, Jian-Ting
core +1 more source
PLoS ONE, 2021 Patients with urothelial carcinoma (UC) experience gemcitabine resistance is a critical issue. The role of hedgehog pathway in the problem was explored.
Yu-Hao Chang +3 more
doaj +1 more source